Lilly files lasmiditan for migraine by Selina McKee | Nov 15, 2018 | News | 0 Eli Lilly has filed an application in the US to market lasmiditan for the acute treatment of migraine with or without aura in adults. Read More
Lilly’s novel migraine drug hits PhIII targets by Selina McKee | Aug 7, 2017 | News | 0 Eli Lilly’s investigational, oral, first-in-class molecule lasmiditan has hit key targets a late-stage trial assessing its safety and efficacy as a treatment for acute migraine, raising hopes for a new approach to managing the condition. Read More